All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Updated Breast Cancer Screening Recommendations Pave the Way for a More Equitable Future

May 16th 2024

Carol M. Mangione, MD, discusses the ramifications of the US Preventative Task Force’s April decision to update the breast cancer screening guidelines.

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

May 15th 2024

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.

Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer

May 15th 2024

Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.

FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 15th 2024

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.

Pertuzumab Plus Trastuzumab Surpasses Prespecified Activity Threshold in ERBB2/3-Altered Biliary Tract Cancer

May 15th 2024

Pertuzumab plus trastuzumab produced antitumor activity and a mild adverse effect profile in patients with pretreated biliary tract cancer with ERBB2/3 alterations.

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC

May 15th 2024

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.

Lower Neighborhood Opportunity Is Linked With Increased Stress, Risk of All-Cause Mortality in Breast Cancer

May 15th 2024

Samilia Obeng-Gyasi, MD, MPH, highlights a study on the association between neighborhood opportunity with all-cause mortality in patients with breast cancer.

Capecitabine or XELOX Does Not Significantly Improve Efficacy vs PF in Inoperable ESCC

May 15th 2024

Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma.

FDA Approves HPV Self-Collection Test for Cervical Cancer

May 15th 2024

The FDA has approved one of the first HPV self-collection solutions, which can be used to identify women who are at risk of developing cervical cancer.

Georgetown’s Cancer Center Awarded Top Designation by National Cancer Institute; Comprehensive Cancer Center Consortium Includes Hackensack Meridian’s John Theurer Cancer Center

May 15th 2024

The National Cancer Institute has awarded “comprehensive cancer center” status to Georgetown University‘s Lombardi Comprehensive Cancer Center.

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC

May 15th 2024

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC.

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

May 14th 2024

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

Guideline-Concordant Care Is Associated With Reduced Risk of Death in Metastatic Osteosarcoma

May 14th 2024

R. Lor Randall, MD, FACS, detailed research into the relationship between guideline-concordant care and survival outcomes in patients with osteosarcoma in California.

Identifying Individual Social Determinants of Health Could Reduce Barriers to Breast Cancer Care

May 14th 2024

Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Pirtobrutinib Transforms SOC in Later-Line CLL/SLL

May 14th 2024

Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.

Relatlimab Plus Nivolumab/Chemo Misses ORR End Point in LAG-3+ Advanced Gastric/GEJ Cancer

May 14th 2024

Relatlimab plus nivolumab and chemotherapy did not improve responses in untreated advanced gastric or GEJ cancer with a LAG-3 expression of at least 1%.

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Sylvester Brain Tumor Institute Launches to Personalize Brain Cancer Treatment

May 14th 2024

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine announced the formation of the Sylvester Brain Tumor Institute.

Applying the Heterogeneous Approach From NSCLC to SCLC

May 14th 2024

Anne Chiang, MD, PhD, discusses understanding the heterogeneity of SCLC to determine which patients will respond to targeted therapy.